31st week of 2013 patent applcation highlights part 40 |
Patent application number | Title | Published |
20130195856 | METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONIST - The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug. | 2013-08-01 |
20130195857 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the overall and/or progression-free survival of the patient. The present invention further provides methods for assessing the sensitivity or responsiveness of a pancreatic cancer patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, using similar methods. | 2013-08-01 |
20130195858 | TREATMENT OF B-CELL LYMPHOMA WITH MICRORNA - The invention relates to microRNA-34a and related microRNAs for use in the treatment of B-cell lymphoma. Likewise it relates to microRNA-34a for use in the preparation of a medicament for the treatment of B-cell lymphoma, and for a method of treatment of B-cell lymphoma comprising administering microRNA-34a. These claims are based on the observation that microRNA-34a shows strong anti-proliferative effects when overexpressed in diffuse large B-cell lymphoma (gDLBCL) cell lines, or when delivered intratumorally or systemically in xenograft models of DLBCL. | 2013-08-01 |
20130195859 | Compositions and methods for modulating cardiac conditions - Embodiments herein report methods and compositions for treating cardiac conditions. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating a subject having or suspected of undergoing cardiac remodeling after a cardiac event. Other embodiments herein relate to compounds including naturally occurring and synthetic compositions of alpha-1 antitrypsin and fragments thereof. | 2013-08-01 |
20130195860 | Antibody targeting through a modular recognition domain - The present invention provides antibodies containing one or more modular recognition domains (MRDs) for targeting the antibodies to specific sites. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also provided in the invention. | 2013-08-01 |
20130195861 | SERUM AMYLOID P-ANTIBODY FUSION PROTEINS - Functionalized pentraxin-2 (PTX-2) protomers and functionalized PTX-2 pentamers, methods for preparing functionalized PTX-2 protomers and functionalized PTX-2 pentamers, pharmaceutical compositions including functionalized PTX-2 pentamers, and methods for using the same are described herein. | 2013-08-01 |
20130195862 | ACTIVIN-ACTRIIA ANTAGONISTS FOR INHIBITING GERM CELL MATURATION - In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation. | 2013-08-01 |
20130195863 | Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases - The invention relates to methods and pharmaceutical compositions for the treatment of bone density related diseases. More particularly, the present invention relates to a ROBO1 modulator for use in a method for the treatment of a bone mineral density related disease in a subject. In a particular embodiment the ROBO1 modulator is selected from the group consisting of small organic molecules, antibodies, aptamers or polypeptides. In another particular embodiment said bone mineral density related disease is selected from the group consisting of ghosal hematodiaphyseal dysplasia syndrome (GHDD), osteoporosis, osteoporosis associated to pseudoglioma, osteoporosis and oculocutaneous hypopigmentation syndrome, osteoporosis due to endocrinological dysfunction, osteogenesis imperfecta osteopenia, Paget's disease, osteomyelitis, hypercalcemia, osteonecrosis, hyperparathyroidism, lytic bone metastases, periodontitis, bone loss due to immobilization and osteoporosis associated with a disease selected from the group consisting of cachexia, anorexia, alopecia, rheumatoid arthritis, psoriatic arthritis, psoriasis, and inflammatory bowel disease. | 2013-08-01 |
20130195864 | FGFR-FC FUSION PROTEIN AND USE THEREOF - The present invention belongs to the field of biotechnology and relates to the treatment of diseases, especially the treatment of FGF overexpression-related diseases. Particularly, the present invention relates to FGFR-Fc fusion proteins and the use thereof in the treatment of angiogenesis regulation-related diseases. More particularly, the present invention relates to isolated soluble FGFR-Fc fusion proteins and their applications in manufacture of the medicament for the treatment of angiogenesis regulation-related diseases. | 2013-08-01 |
20130195865 | METHOD OF PREVENTING THE DEVELOPMENT OF RHEUMATOID ARTHRITIS IN SUBJECTS WITH UNDIFFERENTIATED ARTHRITIS - The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule. | 2013-08-01 |
20130195866 | METHODS TO INHIBIT NEURODEGENERATION - Disclosed herein are methods, and compositions for inhibiting neurodegeneration, e.g., in neuronal cells. The methods and compositions the invention can be used to treat a neurodegenerative disorder, e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, and frontotemproal dementia. In some embodiments, the methods and compositions can be used to inhibit neurodegeneration, e.g., caused by tau-mediated synaptic neurodegeneration, encephalitis, brain trauma, or any disorder suffering from weakening synapses. | 2013-08-01 |
20130195867 | RNA-CODED ANTIBODY - The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-immune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes and in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method. | 2013-08-01 |
20130195868 | TREATING SURFACE OF THE EYE DISORDERS - Disclosed herein are methods for administering an IL-1 or IL-17 antagonist for treating ocular surface disorders, e.g., a dry eye disorder. The antagonists can be administered topically using an opthalmic composition. | 2013-08-01 |
20130195869 | ANTI-HUMAN CCR7 ANTIBODY, HYBRIDOMA, NUCLEIC ACID, VECTOR, CELL, PHARMACEUTICAL COMPOSITION, AND ANTIBODY-IMMOBILIZED CARRIER - An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer. | 2013-08-01 |
20130195870 | ERBB3 Mutations In Cancer - The present invention concerns somatic ErbB3 mutations in cancer including methods of identifying, diagnosing, and prognosing ErbB3 cancers, as well as methods of treating cancer, including certain subpopulations of patients. | 2013-08-01 |
20130195871 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins that bind two different (e.g., nonoverlapping) epitopes of the same receptor or two different receptors expressed on the same cell are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 2013-08-01 |
20130195872 | ANTI-IL-17A/IL-17F CROSS-REACTIVE ANTIBODIES AND METHODS OF USE THEREOF - This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic. | 2013-08-01 |
20130195873 | CARBOHYDRATE HAPTEN-BASED ANTI-CANCER VACCINES AND ANTIBODY DRUGS - Immunogenic compositions that contain haptens consisting of carbohydrate moieties are useful to induce an immune response to provide antibodies to epitopes contained in CA215 and also to elicit an immune response to cancers expressing these epitopes. | 2013-08-01 |
20130195874 | ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR REDUCING THE RISK OF MORTALITY IN A PATIENT HAVING A CHRONIC OR ACUTE DISEASE OR ACUTE CONDITION - According to the present invention it has been found that the administration of an anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold may reduce considerably the risk of mortality in a patient having a severe chronical or acute disease. In a preferred embodiment of the present invention said anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold binds to a region of ADM that is located in the N-terminal part (aa 1-21) of adrenomedullin, (see FIG. | 2013-08-01 |
20130195875 | ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR AN ANTI-ADM NON-IG SCAFFOLD FOR USE IN THERAPY - Subject matter of the present invention is an anti-adrenomedullin antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold wherein said antibody or said fragment or scaffold is a non-neutralizing antibody, antibody fragment or non-Ig scaffold, respectively. | 2013-08-01 |
20130195876 | HUMAN STREPTOCOCCUS PNEUMONIAE ANTIBODIES AND USES THEREFOR - The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of | 2013-08-01 |
20130195877 | TREATMENT OF CACHEXIA BY TARGETING INTERLEUKIN-1 BETA - Administration of a mAb that specifically binds IL-1β is used for treating cachexia in human subjects. | 2013-08-01 |
20130195878 | ANTI-ASIC1 ANTIBODIES AND USES THEREOF - The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders. | 2013-08-01 |
20130195879 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY - The present invention relates to combination therapy using compound of formula (I): | 2013-08-01 |
20130195880 | Identification of Polymorphisms and Their Use as Markers for Disease Susceptibility, Diagnosis and Treatment Optimization - Provided are methods and kits to determine whether a subject is predisposed to developing a disease or condition associated with structural polymorphisms in genes CNTNAP2 and CNTNAP4, along with the methods to optimize treatment with various pharmaceutical preparations which modulate ion channels, neurite outgrowth, and myelination signaling. | 2013-08-01 |
20130195881 | POTENT, STABLE AND NON-IMMUNOSUPPRESSIVE ANTI-CD4 ANTIBODIES - Novel antibodies and their fragments are disclosed that specifically bind to CD4. Anti-CD4 antibodies are disclosed having amino acid substitutions in the hinge region that prevent intrachain disulfide bond formation resulting in antibody molecules with surprisingly improved bivalent stability. Increased stability facilitates manufacturing and provides increased in vivo stability. Antibodies are also disclosed that have amino acid substitutions that reduce binding to Fc receptor and ADCC activity that also result in a surprising effect on CD4 internalization. In addition, genes for such antibodies are disclosed that have been modified such that they have increased expression over their unmodified counterparts. | 2013-08-01 |
20130195882 | MCPIP PROTECTION AGAINST OSTEOCLAST PRODUCTION - Disclosed herein are methods of treating a patient at risk of developing an inflammatory joint disease. In exemplary embodiments, the method involves inhibiting MCPIP levels in a patient in need, wherein said patient in need is exhibiting pre-arthritic or pre-osteoporotic symptoms. | 2013-08-01 |
20130195883 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS - The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method. | 2013-08-01 |
20130195884 | NOVEL MODULATORS OF TRAIL SIGNALLING - The present invention relates to an agent for use as a modulator of apoptosis-factor-associated cell death, apoptosis, cell survival, migration and/or proliferation, a method of diagnosing or monitoring apoptosis-factor-associated conditions or disorders as well as a method of identifying a modulator of apoptosis-factor-associated cell death, apoptosis, cell survival, migration and/or proliferation. Preferably, the invention relates to TRAIL-induced cell death and/or TRAIL-induced apoptosis. Preferably the agents are used to stimulate and/or enable TRAIL-induced cell death or to inhibit TRAIL-induced cell death. The preferable use of the diagnostic tools is to diagnose sensitivity or resistance to TRAIL-induced cell death or induction of sensitivity or resistance to TRAIL-induced cell death by an agent. | 2013-08-01 |
20130195885 | Compositions with Hematopoietic and Immune Activity - The present invention provides methods of using Bv8 and EG-VEGF polypeptides and nucleic acids to promote hematopoiesis. Also provided herein are methods of screening for modulators of Bv8 and EG-VEGF activity. Furthermore, methods of treatment using Bv8 and EG-VEGF polypeptides or Bv8 and EG-VEGF antagonists are provided. | 2013-08-01 |
20130195886 | Methods for Fructanase and Fructokinase Inhibition - Provided are methods and compositions method for inhibiting fructokinase activity within the gastrointestinal tract cell of a subject. The compositions and methods treat or prevent conditions associated with increased permeability and oxidative stress in the gastrointestinal tract of a subject. | 2013-08-01 |
20130195887 | PHARMACOLOGICAL VITREOLYSIS - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy. | 2013-08-01 |
20130195888 | ULTRAFILTRATION AND DIAFILTRATION FORMULATION METHODS FOR PROTEIN PROCESSING - Disclosed herein are methods of purifying proteins using ultrafiltration and diafiltration processes. | 2013-08-01 |
20130195889 | TRABECULECTOMY OUTCOME - The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of an anti-PlGF antibody or fragment thereof. | 2013-08-01 |
20130195890 | TREATMENT OF MS WITH GOAT SERUM - A serum composition from a goat immunised with HIV contains anti-HLA antibody and is suited for palliative improvement of the condition of an animal. | 2013-08-01 |
20130195891 | Micro-RNA family that Modulates Fibrosis and Uses Thereof - The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease. | 2013-08-01 |
20130195892 | BVDV VACCINE - The present invention relates to BVD virus and to its uses, to vaccines and combination vaccines comprising such a virus, their use as a medicament, their use in the treatment of Bovine Viral Diarrhoea and to methods for the preparation of such vaccines. | 2013-08-01 |
20130195893 | USE OF A PNEUMOCOCCAL P4 PEPTIDE FOR ENHANCING OPSONOPHAGOCYTOSIS IN RESPONSE TO A PATHOGEN - Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present on the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a. | 2013-08-01 |
20130195894 | DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS - Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand. | 2013-08-01 |
20130195895 | METHODS OF MODULATING IMMUNE RESPONSES BY MODULATING TIM-1, TIM-2 AND TIM-4 FUNCTION - The invention relates to methods of modulating immune responses in a subject such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them. | 2013-08-01 |
20130195896 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A NEOPLASIA - The invention provides methods for the treatments of neoplasia featuring agents that interfere with the expression or activity of a TNFa receptor. | 2013-08-01 |
20130195897 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE - The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content. | 2013-08-01 |
20130195898 | MICROEMULSIONS WITH ADSORBED MACROMOLECULES AND MICROPARTICLES - Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided. Methods of stimulating an immune response, methods of immunizing a host animal against a viral, bacterial, or parasitic infection, and methods of increasing a Th1 immune response in a host animal by administering to the animal an immunogenic composition of the microparticles, and/or microemulsions of the invention, are also provided. | 2013-08-01 |
20130195899 | THERAPEUTIC IMMUNE MODULATION BY STEM CELL SECRETED EXOSOMES - Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells. Specifically, in one embodiment stem cell derived exosomes are used as a method of treating an autoimmune condition such as rheumatoid arthritis, multiple sclerosis, or systemic lupus erythromatosis. | 2013-08-01 |
20130195900 | IDENTIFICATION OF T CELL TARGET ANTIGENS - The present invention relates to a method of identifying a target antigen of T cells comprising (a) contacting (aa) cells expressing (i) a functional T cell receptor complex comprising predefined matching T cell receptor α and β chains; and (ii) a read-out system for T cell activation; with (ab) antigen-presenting cells carrying (iii) peptide libraries encoded by randomised nucleic acid sequences; and (iv) MHC molecules recognised by the T cell receptor of (i); (b) assessing T cell activation using said read-out system; (c) isolating antigen-presenting cells that are in contact with the cells in which the read-out system indicates T cell activation; (d) identifying the target antigen or the nucleic acid molecule encoding said target antigen. | 2013-08-01 |
20130195901 | SSX-2 PEPTIDE ANALOGS - Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed. | 2013-08-01 |
20130195902 | RECOMBINANT ALLERGEN - Dander from the domestic cat ( | 2013-08-01 |
20130195903 | COMPOSITIONS FOR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES AND ASTHMA - The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma. | 2013-08-01 |
20130195904 | HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) HIGHLY CONSERVED AND LOW VARIANT SEQUENCES AS TARGETS FOR VACCINE AND DIAGNOSTIC APPLICATIONS - We identified regions of the HIV-1 proteome with high conservation, and low variant incidence. Such highly conserved sequences have direct relevance to the development of new-generation vaccines and diagnostic applications. The immune relevance of these sequences was assessed by their correlation to previously reported human T-cell epitopes and to recently identified human HIV-1 T-cell epitopes (identified using HLA transgenic mice). We identified (a) sequences specific to HIV-1 with no shared identity to other viruses and organisms, and (b) sequences that are specific to primate lentivirus group, with multiclade HIV-1 conservation. | 2013-08-01 |
20130195905 | Composition for Preventing or Treating Cervical Cancer Having Human Papillomavirus Plasmodium and Immunity Enhancer - A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18. | 2013-08-01 |
20130195906 | H3 EQUINE INFLUENZA A VIRUS - The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof. | 2013-08-01 |
20130195907 | OMV VACCINES - The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of | 2013-08-01 |
20130195908 | Molecular Complex for Targeting Antigens Towards Cells Comprising Antigens and Uses Thereof for Vaccination - The invention relates to a molecular complex for targeting the antigen towards cells comprising antigens, including at least one antigen associated with at least two ligands of surface molecules of cells comprising antigens, said complex including at least one first ligand of a sulphated sugar of the glycosaminoglycan family and a second ligand of a specific surface molecule of cells comprising antigens, and said first ligand being covalently bonded with said antigen and/or said second ligand. | 2013-08-01 |
20130195909 | Composite Antigenic Sequences and Vaccines - The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection. | 2013-08-01 |
20130195910 | VACCINE DELIVERY METHOD - The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions. | 2013-08-01 |
20130195911 | Compositions And Methods For Treating Skin - A skin treatment composition comprising a combination of at least one extract from the | 2013-08-01 |
20130195912 | Poxvirus Expression System - There is provided a method for inserting a nucleic acid sequence that encodes a foreign peptide into a poxvirus genome, said method comprising: identifying in the poxvirus genome a poxvirus open reading frame wherein said open reading frame is characterised by an initial ATG start codon and wherein expression of said open reading frame is driven by an operably-linked poxvirus promoter located upstream of the open reading frame and wherein expression of said open reading frame provides a peptide that is non-essential to viability of the poxvirus; and inserting the nucleic acid sequence that encodes the foreign peptide at a position downstream of the poxvirus promoter; wherein following said insertion, (i) the nucleic acid that encodes the foreign peptide is operably-linked to the poxvirus promoter and expression of said nucleic acid is driven by said poxvirus promoter; and (ii) translation of the foreign peptide is initiated at an ATG start codon located at the same position as the ATG start codon of the poxvirus open reading frame. Also provided are a poxvirus vector and corresponding uses of the poxvirus vector in medicine. | 2013-08-01 |
20130195913 | LIVE ATTENUATED PARVOVIRUS - The invention relates to live attenuated parvoviruses, their uses, vaccines comprising such live attenuated parvoviruses, as well as methods for their production. | 2013-08-01 |
20130195914 | Expression Of Positive Sense Single Stranded RNA Virus And Uses Thereof - The invention relates to the fields of viruses, vaccines and compounds and methods for expression. In particular, the invention includes methods and agents capable of producing quantities of a vaccine to a positive sense single stranded RNA (“(+)sense RNA”)virus. | 2013-08-01 |
20130195915 | Influenza C Virus and Vaccine - A novel influenza C virus with only low homology to any influenza C virus previously characterized. Challenge studies show that the virus can infect pigs and be transmitted between pigs. Additionally, influenza C is commonly thought of as a human pathogen and serological studies have been performed, looking at the incidence of antibodies against this virus in both pigs and humans. Approximately 10% of pigs and 30% of humans have antibodies to this virus. Additional experimental data show that the virus can infect and transmit in ferrets (a surrogate for human infection studies). In a third aspect, the present invention is the partial genome of this novel influenza C virus. In another aspect, the present invention is a method of detection in animals of this novel influenza C virus. | 2013-08-01 |
20130195916 | System and Method for Identifying Complex Patterns of Amino Acids - A method and system are disclosed for identifying and/or locating complex patterns in an amino acid sequence stored in a computer file or database. According to an aspect of the present invention, techniques are provided to facilitate queries of protein databases. For protein descriptions received in response to the queries, embodiments of the present invention may scan the received protein descriptions to identify and locate Replikin patterns. A Replikin pattern is defined to be a sequence of 7 to about 50 amino acids that include the following three (3) characteristics, each of which may be recognized by an embodiment of the present invention: (1) the sequence has at least one lysine residue located six to ten amino acid residues from a second lysine residue; (2) the sequence has at least one histidine residue; and (3) at least 6% of the amino acids in the sequence are lysine residues. | 2013-08-01 |
20130195917 | IMMUNOADJUVANT - The invention thus relates to a method for boosting the efficiency of a vaccine by co-administering a probiotic bacterium such as | 2013-08-01 |
20130195918 | Equine Herpesvirus 1 Vaccine and Vector and Uses Thereof - We have constructed a mutant EHV-1 that is lacking the entire 12.7 kbp IR segment of the viral genome and found the mutant EHV-1 to be replication competent, to have the ability to replicate in mammalian cell types (including human cells), and to exhibit reduced virulence in the mouse model of EHV-1 virulence. | 2013-08-01 |
20130195919 | INDUCED DENDRITIC CELL COMPOSITIONS AND USES THEREOF - The invention provides, for example, compositions comprising induced tolerogenic dendritic cells which are capable of suppressing an antigen specific T cell-mediated immune response, and to methods of making and using the same. The invention also provides compositions comprising induced immunogenic dendritic cells and methods of making and using them. | 2013-08-01 |
20130195920 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS - The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid. | 2013-08-01 |
20130195921 | METHODS FOR REGULATING GELATION OF HYDROGEL SOLUTIONS AND USES THEREOF - The present invention provides a method for preparing chitosan and xylan composite thereto-gelling solutions to allow regulating the conditions in which the chitosan and xylan solution will gel. The present invention also provides methods for using chitosan/xylan solutions as compositions and for using chitosan/xylan solutions in vitro and in vivo. A thermally-responsive composite hydrogel has been developed and synthesized from the natural polymers chitosan and xylan. The new material is a viscous liquid at room temperature, but turns to a solid gel at physiological temperature (37 C). Rate of gelation is controlled with addition of a salt solution. Applications are for tissue engineering and local delivery of therapeutic agents, including proteins and drugs, as wells as cells. | 2013-08-01 |
20130195922 | METHODS AND COMPOSITIONS FOR TREATING PROLIFERATIVE DISEASES - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 2013-08-01 |
20130195923 | MICROEMULSIONS WITH ADSORBED MACROMOLECULES AND MICROPARTICLES - Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided. Methods of stimulating an immune response, methods of immunizing a host animal against a viral, bacterial, or parasitic infection, and methods of increasing a Th1 immune response in a host animal by administering to the animal an immunogenic composition of the microparticles, and/or microemulsions of the invention, are also provided. | 2013-08-01 |
20130195924 | WATER-SOLUBLE PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE THERAPEUTICALLY ACTIVE SUBSTANCE HAVING HYDROPHOBIC PROPERTIES AND AT LEAST ONE COMPOUND SELECTED FROM AMONG SIALOGLYCOSPHINGOLIPIDS, GLYCOSPHINGOLIPIDS OR A MIXTURE OF SIALOGLYCOSPHINGOLIPIDS AND GLYCOSPHINGOLIPIDS - This invention discloses water soluble pharmaceutical compositions including at least one therapeutically active substance and at least one compound selected from the sialoglycosphingolipids, the glycosphingolipids or a mixture of sialoglicosphingolipids and glycosphingolipids, in which at least one of the therapeutically active substances is a drug with hydrophobic characteristics. In particular, sterile compositions for i.v. administration, composed of nano-glycosphingolipids micelles or modified glycosphingolipids, which can be coated with albumin in a noncovalent form and which allow transport and controlled release of highly hydrophobic molecules are disclosed. | 2013-08-01 |
20130195925 | ANTI AGING APPLICATION AND METHOD FOR TREATING AGING - There is a topical anti-aging composition which is configured to interfere with the production of tyrosinase, as well as melanin by reacting with melanocytes as well as reacting with, or acting on keratinocytes. The anti-aging composition comprises an emulsion comprising a plurality of active ingredients comprising a plurality of pigmentation reducing elements which are configured to interrupt or prevent the production of tyrosinase and melanin. In addition there are a plurality of antioxidants a plurality of anti wrinkling agents a plurality of anti-inflammatory agents at least one additional agent comprising at least one of an emollient, a proactant and a conditioning agent. | 2013-08-01 |
20130195926 | MODULATION OF NITRIC OXIDE SIGNALING TO NORMALIZE TUMOR VASCULATURE - The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic guanosine monophosphate (cGMP) or cGMP dependent protein kinase G production in the tumor vasculature to an amount effective to normalize tumor vasculature and administering an anti-tumor therapy to the subject. | 2013-08-01 |
20130195927 | CERIUM OXIDE NANOPARTICLES AND ASSOCIATED METHODS FOR PROMOTING WOUND HEALING - Novel compositions and methods for the treatment and promotion of wound healing are disclosed herein. There is included a method for treating a wound including administering to a subject in need thereof a wound composition comprising an effective amount of ceria nanoparticles. | 2013-08-01 |
20130195928 | CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH - The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition. | 2013-08-01 |
20130195929 | ACTIVE INGREDIENT DELIVERY SYSTEM WITH AN AMORPHOUS METAL SALT AS CARRIER - An active ingredient delivery system and a method of making or using the same, wherein the delivery system includes an active ingredient and a carrier component of an amorphous metal salt, with the active ingredient at least partly fixed to and partly encapsulated by the carrier component. The active ingredient may be a bitter tasting polyphenol such as a flavonoid. | 2013-08-01 |
20130195930 | Inulin and Inulin Acetate Formulations - The disclosure provides compositions that include microparticles or nanoparticles of beta inulin or inulin acetate and an active agent, where the active agent is contained within individual microparticles or nanoparticles. The active agent can be, for example, a vaccinating antigen, an antigenic peptide sequence, or an immunoglobulin. The compositions can be incorporated into various formulations for administration to a subject such as a human or animal. The invention further provides methods of using the compositions and formulations, including methods of stimulating an immune response in a subject, or enhancing an immune response in a subject, for the purpose of treating, preventing, or inhibiting an infectious disease, autoimmune disease, immunodeficiency disorder, neoplastic disease, degenerative disease, an aging disease, or a combination thereof. | 2013-08-01 |
20130195931 | ANTIMICROBIAL COMPOSITE - An antimicrobial composite which comprises a first, liquid-permeable layer which is substantially completely bonded to a second liquid-absorbing layer. The first layer comprises a coating of at least one antimicrobial metal as such on the side which is bonded to the second layer. Substantially no antimicrobial metal in elemental form is present on exterior surfaces of the composite. | 2013-08-01 |
20130195932 | ARCHAEAL POLAR LIPID AGGREGATES FOR ADMINISTRATION TO ANIMALS - The invention provides non-replicating compositions, and methods for the delivery of these compositions containing pharmaceuticals, biologically relevant molecules, and/or antigens to the host, by administration via a mucosal route such as the intranasal. This invention provides non-replicating vaccine compositions and methods for the delivery of antigens in these vaccine compositions comprising an antigen and a self-adjuvanting carrier, useful for inducing antigen-specific mucosal and systemic immune responses in the host upon immunization via a mucosal route such as intranasal. The vaccine compositions comprise multivalent cations in association with a plurality of spherical archaeal polar lipid aggregates containing aqueous compartments, the AMVAD structure, formed by the interaction of archaeosomes and antigen(s) with multivalent cations such as Ca | 2013-08-01 |
20130195933 | PHARMACEUTICAL COMPOSITION AND USE - An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided. | 2013-08-01 |
20130195934 | METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY - Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug. | 2013-08-01 |
20130195935 | ABUSE-PROOFED DOSAGE FORM - A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid. | 2013-08-01 |
20130195936 | OPHTHALMIC OIL-IN-WATER EMULSIONS CONTAINING PROSTAGLANDINS - The present invention refers to an oil-in-water emulsion for ophthalmic application comprising at least one prostaglandin as active agent and a surfactant component comprising a combination of at least two non-ionic surfactants. The emulsion is suitable for medical applications, particularly for the treatment of glaucoma, and has an increased chemical stability of the prostaglandin active agent so to allow long-term storage also at room temperature. | 2013-08-01 |
20130195937 | USE OF CARBON NANOTUBES FOR PREVENTING OR TREATING BRAIN DISEASE - A method for preventing or treating a brain nervous disease includes administering to a subject in need thereof a therapeutically effective amount of a carbon nanotube, wherein the nervous disease is a brain disease or a traumatic central nervous system injury. The composition of the present invention enables patients to recover from physical damage to the brain, exhibits superior efficacy for inhibiting the onset of Parkinson's disease and strokes in animal models for Parkinson's disease and strokes, and the cytotoxic effects of beta amyloid in beta amyloid toxicity tests. Therefore, the composition of the present invention can be effectively used in the preparation of medicine for protecting cranial nerves, therapeutic agents for preventing or treating brain disease, or therapeutic agents for treating traumatic injuries to the central nervous system. | 2013-08-01 |
20130195938 | METHOD OF MODIFYING DISSOLUTION RATE OF PARTICLES BY ADDITION OF HYDROPHOBIC NANOPARTICLES - Method of modifying dissolution rate of a plurality of particles in an aqueous-based solvent by adding hydrophobic surface modified nanoparticles to the plurality of particles, and exposing the plurality of particles to the aqueous-based solvent. | 2013-08-01 |
20130195939 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF EXENATIDE - This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta. | 2013-08-01 |
20130195940 | METHOD TO INHIBIT RECRUITMENT OF MONOCYTES AND MACROPHAGES BY AN ICAM-3 INHIBITOR - The present disclosure relates generally to methods and materials for modulating the recruitment of macrophages or monocytes to sites at which they may contribute to disease initiation or progression. Embodiments of the disclosure comprise providing a modulator of the activity of ICAM-3 or proximal to the site. | 2013-08-01 |
20130195941 | PULLULAN-CONTAINING POWDER, METHOD FOR PRODUCING THE SAME AND USE THEREOF - The present invention aims to provide a particulate composition containing pullulan, which can be produced without employing any complicated purification step such as solvent precipitation and, when formed into a film, exhibits a higher rupture strength compared to conventional ones; a process for producing the same; and uses thereof. The present invention solves the above object by providing a particulate composition containing pullulan which is produced from a culture obtained by culturing a mutant of a microorganism of the species | 2013-08-01 |
20130195942 | ABRASIVE SYSTEM FOR ORAL CARE COMPOSITIONS - Oral compositions comprising a first and a second abrasive are provided. The first abrasive preferably has an Einlehner hardness of greater than about 5 mg loss per 100,000 revolutions, and the second abrasive preferably has an Einlehner hardness of less than about 5 mg loss per 100,000 revolutions. A ratio of the first abrasive to the second abrasive ranges from about 1:1.6 to about 1.6:1, and the first and second abrasives are preferably present in the oral composition at an amount of about 13% to about 21% by weight, respectively. The pellicle cleaning ratio of the oral composition is greater than 100 and the radioactive dentin abrasiveness is preferably less than 200, and in certain embodiments, preferably less than about 175. Methods of using the oral compositions are also provided. | 2013-08-01 |
20130195943 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS - The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using α | 2013-08-01 |
20130195944 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS - The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using α | 2013-08-01 |
20130195945 | COMPOSITIONS AND METHODS FOR BED BUG CONTROL USING ENTOMOPATHOGENIC FUNGI - Barrier treatment compositions using conidia of entomopathogenic fungi and methods for applying and using the same for bed bug population control and prevention are disclosed. The compositions and methods of the invention provide residual biopesticides control for bed bug populations using barrier treatment compositions transferring conidia of entomopathogenic fungi to a population of bed bugs providing effective kill within about 24 hours to about 10 days. The compositions and methods provide significantly enhanced horizontal transmission of the conidia of the entomopathogenic fungi providing enhanced bed bug control without detrimental effects of bed bug tolerance, resistance and/or negative impact on humans or animals contacting the residual biopesticides. | 2013-08-01 |
20130195946 | INSECTICIDAL HYDROGEL FEEDING SPHERES - Unique spherically shaped insecticidal hydrogel feeding spheres are described comprising insecticide active, food source, optional adjuvant, water, and super-absorbent polymer. The large discrete spheres with diameters of about 2 mm to about 6 mm are made possible by the use of coarse dry granulated polyacrylamide/acrylates copolymer having particle size of from about 1 mm to about 4 mm. The insecticidal hydrogel bait spheres may be placed out in the environment to control insects without the need for a bait station enclosure. The present invention also comprises a method for producing the large discrete bait spheres. | 2013-08-01 |
20130195947 | BIOCIDE POWDER FORMULATION - A storage stable, free flowing powder concentrate for use in the manufacture of a biocide formulation comprises a t biocide containing an iodopropynyl group and an inert filler, wherein the wt % ratio of biocide: inert filler is from about 1:1 to about 1:100 and the wt % of biocide is not more than 50%. | 2013-08-01 |
20130195948 | Composition - There is provided an anti-fouling composition comprising
| 2013-08-01 |
20130195949 | Antimicrobial Layer For Chromatographic Containers - A chromatographic container ( | 2013-08-01 |
20130195950 | HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY - The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug. | 2013-08-01 |
20130195951 | HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY - The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug. | 2013-08-01 |
20130195952 | EXTENDED OR CONTINUOUS WEAR SILICONE HYDROGEL CONTACT LENSES FOR THE EXTENDED RELEASE OF COMFORT MOLECULES - A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed by using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having complexing sites, and cross-linking monomers, which are copolymerized using a suitable initiator. The complexing sites of the recognitive polymeric hydrogel that is formed preferably mimics receptor sites of a target biological tissue, biological recognition, or biological mechanism of action. The system in accordance with an embodiment of the intention is a contact lens for delivering a drug through contact with an eye. | 2013-08-01 |
20130195953 | METHODS AND FORMULATIONS FOR ADMINISTRATION OF ANTI-INFLAMMATORY COMPOUNDS - The invention relates to resolvins and their use as anti-inflammatory compounds. The resolvins may be administered in a variety of forms, including drug depots comprising polymers or lipids. The pharmaceutical formulations of the present invention may be used to treat a variety of conditions including acute pain and chronic pain. | 2013-08-01 |
20130195954 | FILMS AND PARTICLES - Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses. | 2013-08-01 |
20130195955 | Implants Containing BMP-7 - Osoteogenic implants, and related compositions, methods and kits. The implants comprise a biodegradable scaffold comprising a polycaprolactone matrix and tricalcium phosphate particles within the matrix. The implants further include a formulation comprising BMP-7. | 2013-08-01 |